Clinical Trials Browser

Phase 3 × Has announcements × Lymphoid × Clear all

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 2 FDA

Hodgkin Disease

NCT02166463 2026-03-17

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Phase 3 Active not recruiting

600 enrolled 14 charts 1 FDA

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT04404283 2026-03-17

ECHELON-3

Phase 3 Active not recruiting

238 enrolled 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03336333 2026-03-09

SEQUOIA

Phase 3 Active not recruiting

590 enrolled 12 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02730299 2026-02-25

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3 Completed

125 enrolled 18 charts 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Phase 3 Active not recruiting

635 enrolled 3 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01516580 2026-02-09

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

Phase 3 Completed

482 enrolled 2 FDA

Burkitt Lymphoma, Lymphoma, B-Cell

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase 3 Active not recruiting

310 enrolled 18 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03274492 2026-02-06

POLARIX

Phase 3 Active not recruiting

1,000 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT04680052 2025-12-22

InMIND

Phase 3 Active not recruiting

654 enrolled 40 charts 3 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03391466 2025-12-01

ZUMA-7

Phase 3 Completed

359 enrolled 27 charts 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02003222 2025-11-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

488 enrolled 13 charts 2 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02048813 2025-11-28

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Active not recruiting

529 enrolled 12 charts 3 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

245 enrolled 15 charts 2 FDA

LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase 3 Completed

445 enrolled 22 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02475681 2025-08-27

ElevateTN

Phase 3 Active not recruiting

535 enrolled 19 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03575351 2025-08-03

TRANSFORM

Phase 3 Completed

184 enrolled 30 charts 2 FDA

Lymphoma, Non-Hodgkin, Recurrence

NCT05409066 2025-07-28

EPCORE FL-1

Phase 3 Active not recruiting

549 enrolled 5 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT01996865 2025-07-10

MAGNIFY

Phase 3 Completed

503 enrolled 18 charts 2 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04666038 2025-04-20

BRUIN CLL-321

Phase 3 Active not recruiting

238 enrolled 17 charts 3 FDA

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03734016 2025-03-30

ALPINE

Phase 3 Completed

652 enrolled 27 charts 2 FDA

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03836261 2024-12-27

AMPLIFY

Phase 3 Active not recruiting

984 enrolled 3 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03053440 2024-10-26

ASPEN

Phase 3 Completed

201 enrolled 19 charts 2 FDA

Waldenstrom Macroglobulinemia

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 3 Completed

111 enrolled 23 charts 2 FDA

LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Phase 3 Completed

372 enrolled 14 charts 2 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 3 Terminated

405 enrolled 27 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02005471 2023-10-17

MURANO

Phase 3 Completed

389 enrolled 35 charts 4 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02204982 2023-09-28

DYNAMO + R

Phase 3 Terminated

13 enrolled 10 charts 2 FDA

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Phase 3 Completed

319 enrolled 18 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01938001 2023-02-22

AUGMENT

Phase 3 Completed

358 enrolled 18 charts 2 FDA

Lymphoma, Non-Hodgkin

NCT01777152 2021-11-30

ECHELON-2

Phase 3 Completed

452 enrolled 16 charts 2 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT01564784 2019-01-09

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Phase 3 Completed

326 enrolled 33 charts 2 FDA

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma